137 related articles for article (PubMed ID: 30998162)
1. [Effects of Low-Dose Decitabine on Soluble CD44, GDF11 Levels and Hematopoietic Function in Elderly Patients with MDS].
Guo SQ; Shi R; Chen YY; Liu S; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):509-514. PubMed ID: 30998162
[TBL] [Abstract][Full Text] [Related]
2. [Clinical Efficacy of Low-Dose Decitabine alone for Treatment of Myelodysplastic Syndrome].
Shi R; Guo SQ; Chen YY; Liu S; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1568-1573. PubMed ID: 31607313
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
Zhang YP; Wu WZ; Cui GX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1341-4. PubMed ID: 25338585
[TBL] [Abstract][Full Text] [Related]
5. [Clinical Comparation of Two Kinds of Chemotherapy Regimens in the Treatment of Patients with MDS-RAEB/AML-MRC].
Wu XF; Li TT; Sun L; Wang LJ; Ran XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):894-898. PubMed ID: 32552954
[TBL] [Abstract][Full Text] [Related]
6. [Clinical Efficacy Comparison of Ultralow Dose of Decitabine and Cyclosporine on Low-risk and Intermediate-risk Type 1 of Myelodysplastic Syndrome].
Luo X; Wu H; Ding Y; Chen YH; Liang AB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):510-4. PubMed ID: 27151020
[TBL] [Abstract][Full Text] [Related]
7. [The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Gao S; Qiu H; Jin Z; Tang X; Fu Z; Ma X; Han Y; Chen S; Sun A; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):961-5. PubMed ID: 25417868
[TBL] [Abstract][Full Text] [Related]
8. [The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen].
Xu ZF; Qin TJ; Zhang HL; Fang LW; Zhang Y; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):572-577. PubMed ID: 28810323
[No Abstract] [Full Text] [Related]
9. [Efficacy, Prognosis and Safety of Decitabine Combined with Low-Dose Cytarabine in the Treatment of Elderly Patients with Relapsed/Refractory Acute Myeloid Leukemia].
Chen D; Lu Y; Yan RZ; Ye PP; Zhang YS; Ma JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):390-395. PubMed ID: 30998143
[TBL] [Abstract][Full Text] [Related]
10. [Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia].
Huang YQ; Zhang XY; Wu SX; Guo XZ; Pan JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1641-1646. PubMed ID: 29262890
[TBL] [Abstract][Full Text] [Related]
11. [The safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with inermediate or higer-risk myelodysplastic syndrome].
Ai H; Wei XD; Yin QS; Mi RH; Chen L; Wang Q; Song YP
Zhonghua Nei Ke Za Zhi; 2019 Dec; 58(12):908-910. PubMed ID: 31775455
[TBL] [Abstract][Full Text] [Related]
12. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
13. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
Zhang JL; Cao YP; Li JG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):494-503. PubMed ID: 30998160
[TBL] [Abstract][Full Text] [Related]
15. [Outcomes of DNMT3A
Chen YY; Shi R; Guo SQ; Zhang YX; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1292-1297. PubMed ID: 32798414
[TBL] [Abstract][Full Text] [Related]
16. [The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].
Ai H; Wei XD; Yin QS; Wang P; Mi RH; Yuan FF; Chen L; Song YP
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):606-609. PubMed ID: 28789495
[TBL] [Abstract][Full Text] [Related]
17. [Clinical efficacy of decitabine plus improved CAG chemotherapy and haplo-identical donor peripheral lymphocyte infusion regimen on elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia].
Dou LP; Jing Y; Wang QS; Mei JH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):662-6. PubMed ID: 23815918
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
Wu L; Li X; Chang C; Xu F; He Q; Wu D; Zhang Z; Su J; Zhou L; Song L; Chao X; Zhao Y
Leuk Lymphoma; 2016; 57(6):1367-74. PubMed ID: 26397697
[TBL] [Abstract][Full Text] [Related]
19. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS
Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
[TBL] [Abstract][Full Text] [Related]
20. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.
Ye L; Ren Y; Zhou X; Mei C; Xu W; Ma L; Luo Y; Hu C; Ye X; Wei J; Lou Y; Jin J; Tong H
Blood Cells Mol Dis; 2019 Jul; 77():88-94. PubMed ID: 31005752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]